Cardinal Health Inc. has raised its FY25 earnings guidance and set a long-term growth target, signaling a commitment to sustained growth and value creation.
Cardinal Health has launched a groundbreaking medical device, the Kendall DL Multi System, which enables continuous monitoring of three vital signs in a single platform, revolutionizing patient care and driving efficiencies in hospitals.
Cardinal Health’s stock price has shown resilience in a volatile market, with a 52-week high of $156.44 and a 52-week low of $93.17, driven by trends such as increasing demand for healthcare services and advancements in medical technology.
Cardinal Health’s stock price has skyrocketed 64% in just a few months, but investors are left wondering if the company’s growth is sustainable or just a fleeting market trend.
Cardinal Health’s stock price has increased, driven by industry developments such as Eton Pharmaceuticals’ FDA approval for its hydrocortisone oral solution.
Cardinal Health’s stock price closed at $148.22 USD on May 7, 2025, with a 52-week high of $154.07 USD and a 52-week low of $93.17 USD on July 14, 2024.
Cardinal Health’s stock performance is expected to benefit from the growing home healthcare market, driven by factors such as cost efficiency and improved patient outcomes.